RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Financial and othersWell the NASH is on hold is shelved is inactive! The Trogarzo market is much smaller as the docts only prescribe it when patients' current regime fails, lipo is cosmetic so the only this company has a "preclinical" oncology program. Is that all it takes to stay invested in THTX?
It's good to remember they got the letter May proceed from FDA based on 900 patients in phase 3 and post approval 1100 patients for a duration of 60 months despite all the holes in their data. Why would the company add the interim analysis costing 25% more to get EMA onboard if that wouldn't increase the value of their protocol. Would people be more pleased if the company would have stopped with FDA's blessing? Would the program be worth more or more appealing to potential partners if the targeted market was US only ? If yes then one has to question their sanity. How can the program be shelved if they pay folks to actually find a partner?
It is also good to remember sales didn't grow as much as anticipated for one small problem in the last 18 months the covid19 pandemic in fact to have stagnated sales or slightly less than pre pandemic levels is not bad at all.
The point is what the company has done thus far on top of starting the oncology as per schedule and yes they are not in control of the trial's results they also have managed to put together a ready to go program for NASH in the US and Europe so they can move on with the program preferably with a partner failing that without. They brought in marketing expertise to sell their drugs and managed to have a strict cost control. I have criticized their low profile but I applaud them for their progress in the R&D area and trying the best they can to better commercial their drugs. Their decisions so far in both areas makes sense and they have done well where things have been in their control.
As a reminder only few months ago many couldn't believe they could start a phase 3 NASH as their data was not good enough now that they can with the blessings of both agencies only because they made the right strategic decision to share the risks and potential profits their program is worth less?